GEN 1

Drug Profile

GEN 1

Alternative Names: EGEN-001; GEN-1 IL-12 DNA-based immunotherapy - Celsion; IL-12 gene therapy - Celsion Corporation; IL-12 gene therapy - EGEN; IL-12 gene therapy - Expression Genetics; Interleukin-12 gene therapy - Celsion Corporation; Interleukin-12 gene therapy - EGEN; Interleukin-12 gene therapy - Expression Genetics; phIL-12-005/PPC

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Expression Genetics
  • Developer Celsion Corporation
  • Class Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer
  • Preclinical Glioblastoma
  • No development reported Colorectal cancer

Most Recent Events

  • 20 Jan 2017 Interim immunogenicity data from the phase Ib OVATION trial in Ovarian Cancer released by Celsion Corporation
  • 17 Jan 2017 Efficacy data from the phase Ib OVATION trial in Ovarian cancer released by Celsion Corportaion
  • 10 Nov 2016 Efficacy and top-line pharmacodynamics data released from a phase I trial in Ovarian cancer released by Celsion
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top